The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Verona Pharma Plc ADR shares valued at $922,000 were sold by Fisher Andrew on Jun 16 ’25. At $11.53 per share, Fisher Andrew sold 80,000 shares. The insider’s holdings dropped to 359,999 shares worth approximately $37.71 million following the completion of this transaction.
Also, Hahn Mark W sold 400,000 shares, netting a total of over 4,560,360 in proceeds. Following the sale of shares at $11.40 each, the insider now holds 12,278,992 shares.
Before that, ZACCARDELLI DAVID had sold 400,000 shares from its account. In a trade valued at $4,560,520, the President and CEO traded Verona Pharma Plc ADR shares for $11.40 each. Upon closing the transaction, the insider’s holdings decreased to 400,000 shares, worth approximately $1.38 billion.
As published in a research note from H.C. Wainwright on July 14, 2025, Verona Pharma Plc ADR [VRNA] has been rated down from a Buy to a Neutral. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of April 28, 2025, TD Cowen has initiated its “Buy” rating for VRNA. Earlier on April 21, 2025, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for VRNA stock.
Analyzing VRNA Stock Performance
On last trading session,, Verona Pharma Plc ADR [NASDAQ: VRNA] plunged -0.03% to $104.74. The stock’s lowest price that day was $104.72, but it reached a high of $104.905 in the same session. During the last five days, there has been a drop of approximately -0.03%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 403.07%. Shares of the company reached a 52-week high of $104.99 on 07/10/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 104.67, which, if violated, would cause prices to drop to 104.59. In the upper region, resistance lies at 104.86. The next price resistance is at 104.98. RSI (Relative Strength Index) is 70.50 on the 14-day chart, showing overbought technical sentiment.
Is Verona Pharma Plc ADR subject to short interest?
Stocks of Verona Pharma Plc ADR saw a sharp rise in short interest on 2025-06-13 jumping by 0.35 million shares to 8.42 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 8.07 million shares. A jump of 4.13% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.19 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.19.
Which companies own the most shares of Verona Pharma Plc ADR (VRNA)?
In terms of Verona Pharma Plc ADR share price expectations, FactSet research, analysts set an average price target of 107 in the next 12 months, up nearly 2.13% from the previous closing price of $104.77. Analysts anticipate Verona Pharma Plc ADR stock to reach 170 by 2025, with the lowest price target being 80. In spite of this, 7 analysts ranked Verona Pharma Plc ADR stock as Buy at the end of 2025. On January 10, 2025, ROTH MKM assigned a price target of “a Buy” to the stock and initiated coverage with a $68.
